Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$46.97 +0.2%	$48.12	$39.35 ▼ $63.33	$95.36B	0.38	12.92 million shs	9.30 million shs
HZNP Horizon Therapeutics Public	$116.30	$115.72	$60.03 ▼ $116.38	$26.63B	1.03	2.50 million shs	N/A
PFE Pfizer	$24.04 +0.3%	$23.30	$20.92 ▼ $31.54	$136.28B	0.57	41.13 million shs	31.91 million shs
ZTS Zoetis	$157.51 +0.2%	$159.72	$139.70 ▼ $200.33	$69.97B	0.94	2.54 million shs	2.39 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.22%	-3.46%	+0.19%	-20.69%	+12.02%
HZNP Horizon Therapeutics Public	0.00%	0.00%	0.00%	0.00%	0.00%
PFE Pfizer	+0.30%	-1.46%	+3.03%	-5.95%	-13.34%
ZTS Zoetis	+0.16%	-4.17%	-3.32%	-2.34%	-7.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.9518 of 5 stars	3.2	5.0	4.2	4.0	3.5	3.3	1.3
HZNP Horizon Therapeutics Public	1.1556 of 5 stars	0.0	0.0	0.0	3.2	0.6	1.7	1.9
PFE Pfizer	4.859 of 5 stars	2.3	4.0	4.2	4.3	2.3	1.7	3.1
ZTS Zoetis	4.6194 of 5 stars	3.5	3.0	4.2	0.4	3.5	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.48% Upside
HZNP Horizon Therapeutics Public	0.00	N/A	N/A	N/A
PFE Pfizer	2.53	Moderate Buy	$29.17	21.33% Upside
ZTS Zoetis	3.00	Buy	$212.13	34.67% Upside

Current Analyst Ratings Breakdown

Latest BMY, ZTS, PFE, and HZNP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/23/2025	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00
4/22/2025	BMY Bristol Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $55.00
4/22/2025	BMY Bristol Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
4/22/2025	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00
4/14/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$180.00 ➝ $165.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	1.98	$5.90 per share	7.96	$8.08 per share	5.81
HZNP Horizon Therapeutics Public	$3.63B	7.34	$7.05 per share	16.49	$22.38 per share	5.20
PFE Pfizer	$63.63B	2.15	$4.38 per share	5.49	$15.62 per share	1.54
ZTS Zoetis	$9.26B	7.58	$7.09 per share	22.23	$10.57 per share	14.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.59	7.71	1.39	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
HZNP Horizon Therapeutics Public	$521.48M	$1.87	62.19	20.55	3.96	12.02%	20.46%	11.52%	N/A
PFE Pfizer	$8.03B	$1.38	17.42	7.93	0.87	12.62%	20.33%	8.53%	7/29/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	28.28	23.33	2.61	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest BMY, ZTS, PFE, and HZNP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.28%	N/A	92.88%	17 Years
HZNP Horizon Therapeutics Public	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.15%	N/A	124.64%	16 Years
ZTS Zoetis	$2.00	1.27%	N/A	35.91%	14 Years

Latest BMY, ZTS, PFE, and HZNP Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.65	1.28	1.17
HZNP Horizon Therapeutics Public	0.48	4.27	4.09
PFE Pfizer	0.64	1.26	0.96
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
HZNP Horizon Therapeutics Public	80.37%
PFE Pfizer	68.36%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.07%
HZNP Horizon Therapeutics Public	2.20%
PFE Pfizer	0.06%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
HZNP Horizon Therapeutics Public	2,115	228.99 million	223.96 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
ZTS Zoetis	13,800	445.21 million	444.50 million	Optionable

BMY, ZTS, PFE, and HZNP Headlines

Recent News About These Companies

LaFleur & Godfrey LLC Reduces Position in Zoetis Inc. (NYSE:ZTS)

June 24 at 6:21 AM | marketbeat.com

Flagship Harbor Advisors LLC Acquires 1,760 Shares of Zoetis Inc. (NYSE:ZTS)

June 24 at 4:25 AM | marketbeat.com

Oppenheimer Asset Management Inc. Acquires 43,325 Shares of Zoetis Inc. (NYSE:ZTS)

June 23 at 7:19 AM | marketbeat.com

2 S&P 500 Stocks on Our Watchlist and 1 to Think Twice About

June 23 at 6:59 AM | finance.yahoo.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Sawgrass Asset Management LLC

June 23 at 6:15 AM | marketbeat.com

Kentucky Retirement Systems Insurance Trust Fund Lowers Stock Position in Zoetis Inc. (NYSE:ZTS)

June 23 at 5:05 AM | marketbeat.com

Cullinan Associates Inc. Sells 2,400 Shares of Zoetis Inc. (NYSE:ZTS)

June 23 at 4:38 AM | marketbeat.com

Intact Investment Management Inc. Boosts Stake in Zoetis Inc. (NYSE:ZTS)

June 23 at 4:37 AM | marketbeat.com

76,510 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Vantage Investment Partners LLC

June 22 at 6:09 AM | marketbeat.com

Harvey Investment Co. LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 22 at 5:59 AM | marketbeat.com

Wealth Enhancement Advisory Services LLC Sells 157,309 Shares of Zoetis Inc. (NYSE:ZTS)

June 22 at 3:21 AM | marketbeat.com

Fishman Jay A Ltd. MI Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 21 at 7:31 AM | marketbeat.com

Union Savings Bank Lowers Position in Zoetis Inc. (NYSE:ZTS)

June 21 at 7:31 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Holdings Raised by Nilsine Partners LLC

June 21 at 7:09 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Appleton Partners Inc. MA

June 21 at 6:16 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Cabot Wealth Management Inc.

June 21 at 5:59 AM | marketbeat.com

Dupont Capital Management Corp Acquires 27,864 Shares of Zoetis Inc. (NYSE:ZTS)

June 21 at 5:32 AM | marketbeat.com

Covea Finance Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

June 21 at 5:22 AM | marketbeat.com

Envestnet Portfolio Solutions Inc. Has $6.77 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 21 at 4:23 AM | marketbeat.com

Boston Trust Walden Corp Buys 7,542 Shares of Zoetis Inc. (NYSE:ZTS)

June 21 at 4:23 AM | marketbeat.com

Unusually Active Put Options Signal Long Straddle Opportunity After Zoetis Downgrade

June 20, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, ZTS, PFE, and HZNP Company Descriptions

Bristol Myers Squibb NYSE:BMY

$46.97 +0.11 (+0.23%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$47.08 +0.11 (+0.22%)

As of 07:08 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Pfizer NYSE:PFE

$24.04 +0.07 (+0.29%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$24.14 +0.11 (+0.44%)

As of 07:07 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis NYSE:ZTS

$157.51 +0.34 (+0.22%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$158.32 +0.81 (+0.51%)

As of 07:03 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time